42,754 XNAS Volume
XNAS 18 Mar, 2025 12:01 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.81 per share. | 03 Mar 2025 | 1,337 | 79,226 | - | 11.8 | 15,790 | Common Stock |
| Rebecca Kuhn | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.81 per share. | 03 Mar 2025 | 1,337 | 124,895 | - | 11.8 | 15,790 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.56 per share. | 27 Feb 2025 | 1,430 | 80,563 | - | 12.6 | 17,961 | Common Stock |
| Rebecca Kuhn | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.56 per share. | 27 Feb 2025 | 1,430 | 126,232 | - | 12.6 | 17,961 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.72 per share. | 21 Feb 2025 | 78,334 | 81,993 | - | 13.7 | 1,074,844 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 192 | 0 | - | - | Stock Option (Rt to Buy) | |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 192 | 192 | - | - | Stock Option (Rt to Buy) | |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 12,234 | 12,234 | - | - | Stock Option (Rt to Buy) | |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 40,000 | 180,449 | - | - | Stock Option (Rt to Buy) | |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.32 per share. | 21 Feb 2025 | 926 | 85,836 | - | 8.3 | 7,704 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.55 per share. | 21 Feb 2025 | 231 | 85,605 | - | 5.5 | 1,282 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.02 per share. | 21 Feb 2025 | 233 | 85,372 | - | 3.0 | 704 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.98 per share. | 21 Feb 2025 | 264 | 85,108 | - | 3.0 | 787 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 21 Feb 2025 | 5,167 | 79,941 | - | 4.1 | 21,185 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share. | 21 Feb 2025 | 231 | 79,710 | - | 4.3 | 982 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 21 Feb 2025 | 1,303 | 78,407 | - | 4.1 | 5,355 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 21 Feb 2025 | 231 | 78,176 | - | 4.1 | 954 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.93 per share. | 21 Feb 2025 | 1,302 | 76,874 | - | 8.9 | 11,627 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.88 per share. | 21 Feb 2025 | 231 | 76,643 | - | 6.9 | 1,589 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.90 per share. | 21 Feb 2025 | 1,303 | 75,340 | - | 8.9 | 11,597 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.84 per share. | 21 Feb 2025 | 264 | 75,076 | - | 14.8 | 3,918 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.50 per share. | 21 Feb 2025 | 12,474 | 62,602 | - | 17.5 | 218,295 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.99 per share. | 21 Feb 2025 | 1,334 | 61,031 | - | 16.0 | 21,331 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.00 per share. | 21 Feb 2025 | 237 | 61,268 | - | 14 | 3,318 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 21 Feb 2025 | 3,045 | 57,986 | - | 8.0 | 24,299 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.46 per share. | 21 Feb 2025 | 1,335 | 56,511 | - | 6.5 | 8,624 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.65 per share. | 21 Feb 2025 | 237 | 56,414 | - | 7.6 | 1,813 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.24 per share. | 21 Feb 2025 | 3,045 | 53,369 | - | 7.2 | 22,046 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.39 per share. | 21 Feb 2025 | 1,334 | 52,035 | - | 7.4 | 9,858 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.00 per share. | 21 Feb 2025 | 237 | 51,798 | - | 6 | 1,422 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.19 per share. | 21 Feb 2025 | 3,045 | 48,753 | - | 9.2 | 27,984 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.93 per share. | 21 Feb 2025 | 1,413 | 47,340 | - | 11.9 | 16,857 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.04 per share. | 21 Feb 2025 | 265 | 47,075 | - | 14.0 | 3,721 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.23 per share. | 21 Feb 2025 | 3,405 | 43,670 | - | 14.2 | 48,453 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 192 | 43,862 | - | 0.0 | 5 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 192 | 44,054 | - | 0.0 | 5 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 192 | 44,246 | - | 0.0 | 5 | Common stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 12,234 | 56,480 | - | 0.0 | 318 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 40,000 | 96,480 | - | 0.0 | 1,040 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 192 | 0 | - | - | Stock Option (Rt to Buy) | |
| Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 29 Jan 2025 | 100 | 86,962 | - | 15 | 1,500 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 29 Jan 2025 | 200 | 86,762 | - | 15 | 3,000 | Common Stock |
| Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 24 Jan 2025 | 3,200 | 87,062 | - | 15.0 | 48,032 | Common Stock |
| R. Scott Huennekens | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 15,507 | 15,507 | - | - | Stock Option (Right to Buy) | |
| Frank M. Fischer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,774 | 17,774 | - | - | Stock Option (Rt to Buy) | |
| Joseph S. Lacob | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,774 | 17,774 | - | - | Stock Option (Rt to Buy) | |
| Uri Geiger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,774 | 17,774 | - | - | Stock Option (Rt to Buy) | |
| Lisa Andrade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,774 | 17,774 | - | - | Stock Option (Rt to Buy) | |
| Rakhi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,774 | 17,774 | - | - | Stock Option (Rt to Buy) | |
| Renee Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,774 | 17,774 | - | - | Stock Option (Rt to Buy) | |
| Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 24,950 | 24,950 | - | - | Stock Option (Right to Buy) | |
| Joel Becker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 104,720 | 104,720 | - | - | Stock Option (Right to Buy) | |
| Kuhn Rebecca | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 12,500 | 152,204 | - | 0 | Common Stock | |
| Kuhn Rebecca | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 24,950 | 24,950 | - | - | Stock Option (Right to Buy) | |
| Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 12,500 | 90,262 | - | 0 | Common Stock | |
| Becker Joel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 52,470 | 52,470 | - | 0 | Common Stock | |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 50,000 | 140,449 | - | - | Stock Option (Rt to Buy) | |
| Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 12 Feb 2024 | 50,000 | 160,327 | - | 0.0 | 1,300 | Common Stock |
| Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 02 Feb 2024 | 3,446 | 77,762 | - | 15.2 | 52,278 | Common Stock |
| Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 02 Feb 2024 | 14,143 | 81,208 | - | 15.1 | 213,122 | Common Stock |
| Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.08 per share. | 30 Jan 2024 | 1,923 | 96,014 | - | 15.1 | 28,990 | Common Stock |
| Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 30 Jan 2024 | 663 | 95,351 | - | 15.0 | 9,971 | Common Stock |
| Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 30 Jan 2024 | 11,262 | 97,937 | - | 15.1 | 170,004 | Common Stock |
| Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.03 per share. | 24 Jan 2024 | 827 | 109,200 | - | 15.0 | 12,426 | Common Stock |
| Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 24 Jan 2024 | 1 | 109,199 | - | 15 | 15 | Common Stock |
| Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 26 Dec 2023 | 102 | 123,327 | - | 10 | 1,020 | Common Stock |
| Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 26 Dec 2023 | 13,300 | 110,027 | - | 10.1 | 134,648 | Common Stock |
| Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 20 Dec 2023 | 2,730 | 123,429 | - | 10.1 | 27,695 | Common Stock |
| Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.16 per share. | 06 Dec 2023 | 11,005 | 126,159 | - | 8.2 | 89,773 | Common Stock |
| Joel Becker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 380,424 | 380,424 | - | - | Stock Option (Rt to Buy) | |
| Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 225,000 | 407,080 | - | 0 | Common Stock | |
| Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2023 | 80,000 | 137,164 | - | 0 | Common Stock | |
| Rebecca Kuhn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2023 | 80,000 | 139,704 | - | 0 | Common Stock | |
| Irina Ridley | Chief Legal Officer/Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2023 | 80,000 | 141,139 | - | 0 | Common Stock | |
| Uri Geiger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 120,521 | 120,521 | - | - | Stock Option (Right to Buy) | |
| Rebecca Kuhn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 31 Oct 2022 | 692 | 58,968 | - | 0.0 | 18 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 482 | 0 | - | - | Stock Option (Rt to Buy) | |
| Rebecca Kuhn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 254 | 0 | - | - | Stock Option (Rt to Buy) | |
| Rebecca Kuhn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 692 | 0 | - | - | Stock Option (Rt to Buy) | |
| Rebecca Kuhn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 31 Oct 2022 | 482 | 59,704 | - | 0.0 | 13 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 31 Oct 2022 | 254 | 59,222 | - | 0.0 | 7 | Common Stock |
| Joseph S. Lacob | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2022 | 192 | 0 | - | - | Stock Option (Rt to Buy) | |
| Joseph S. Lacob | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 18 Oct 2022 | 192 | 384 | - | 0.0 | 5 | Common Stock |
| Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 07 Oct 2022 | 384 | 57,164 | - | 0.0 | 10 | Common Stock |
| Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2022 | 384 | 0 | - | - | Stock Option (Right to Buy) | |
| Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2022 | 192 | 0 | - | - | Stock Option (Right to Buy) | |
| Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 07 Oct 2022 | 192 | 56,780 | - | 0.0 | 5 | Common Stock |
| Frank M. Fischer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 18,253 | 18,253 | - | - | Stock Option (Right to Buy) | |
| Joseph S. Lacob | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 18,253 | 18,253 | - | - | Stock Option (Right to Buy) | |
| Lisa Andrade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 18,253 | 18,253 | - | - | Stock Option (Right to Buy) | |
| Greg S. Garfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 18,253 | 18,253 | - | - | Stock Option (Right to Buy) | |
| Rakhi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 18,253 | 18,253 | - | - | Stock Option (Right to Buy) | |
| Renee Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 18,253 | 18,253 | - | - | Stock Option (Right to Buy) | |
| Irina Ridley | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 5.78 per share. | 08 Jun 2022 | 2,500 | 61,139 | - | 5.8 | 14,445 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.23 per share. | 22 Apr 2022 | 3,405 | 127,662 | - | 14.2 | 48,453 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 22 Apr 2022 | 3,045 | 128,960 | - | 8.0 | 24,299 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.46 per share. | 22 Apr 2022 | 1,334 | 127,626 | - | 6.5 | 8,618 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.65 per share. | 22 Apr 2022 | 237 | 127,389 | - | 7.6 | 1,813 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.24 per share. | 22 Apr 2022 | 3,045 | 124,344 | - | 7.2 | 22,046 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.39 per share. | 22 Apr 2022 | 1,334 | 123,010 | - | 7.4 | 9,858 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.00 per share. | 22 Apr 2022 | 237 | 122,773 | - | 6 | 1,422 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.19 per share. | 22 Apr 2022 | 3,045 | 119,728 | - | 9.2 | 27,984 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.93 per share. | 22 Apr 2022 | 1,334 | 118,394 | - | 11.9 | 15,915 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.04 per share. | 22 Apr 2022 | 265 | 118,129 | - | 14.0 | 3,721 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.32 per share. | 22 Apr 2022 | 718 | 151,486 | - | 8.3 | 5,974 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.55 per share. | 22 Apr 2022 | 179 | 151,307 | - | 5.5 | 993 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.02 per share. | 22 Apr 2022 | 181 | 151,126 | - | 3.0 | 547 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.98 per share. | 22 Apr 2022 | 212 | 150,914 | - | 3.0 | 632 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 22 Apr 2022 | 4,019 | 146,895 | - | 4.1 | 16,478 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share. | 22 Apr 2022 | 179 | 146,716 | - | 4.3 | 761 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 22 Apr 2022 | 1,010 | 145,706 | - | 4.1 | 4,151 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 22 Apr 2022 | 179 | 145,527 | - | 4.1 | 739 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.93 per share. | 22 Apr 2022 | 1,010 | 144,517 | - | 8.9 | 9,019 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.88 per share. | 22 Apr 2022 | 179 | 144,338 | - | 6.9 | 1,232 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.90 per share. | 22 Apr 2022 | 1,010 | 143,328 | - | 8.9 | 8,989 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.84 per share. | 22 Apr 2022 | 212 | 143,116 | - | 14.8 | 3,146 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.50 per share. | 22 Apr 2022 | 9,832 | 133,284 | - | 17.5 | 172,060 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.99 per share. | 22 Apr 2022 | 1,042 | 132,242 | - | 16.0 | 16,662 | Common Stock |
| Rebecca Kuhn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.00 per share. | 22 Apr 2022 | 237 | 132,005 | - | 14 | 3,318 | Common Stock |
| Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 155,080 | 182,080 | - | 0 | Common Stock | |
| Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 310,160 | 310,160 | - | - | Stock Option (Right to Buy) | |
| Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 93,530 | 93,530 | - | - | Stock Option (Right to Buy) | |
| Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 46,760 | 56,588 | - | 0 | Common Stock | |
| Rebecca Kuhn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 46,740 | 58,276 | - | 0 | Common Stock | |
| Rebecca Kuhn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 93,480 | 93,480 | - | - | Stock Option (Right to Buy) | |
| Irina Ridley | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 56,987 | 63,639 | - | 0 | Common Stock | |
| Irina Ridley | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 83,530 | 83,530 | - | - | Stock Option (Right to Buy) | |
| Irina Ridley | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 7.54 per share. | 28 Feb 2022 | 1,470 | 6,652 | - | 7.5 | 11,082 | Common Stock |
| Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 27,000 | 27,000 | - | 0 | Common Stock | |
| Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 54,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
| Martha Morrell | Chief Medical officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 8,310 | 9,828 | - | 0 | Common Stock | |
| Martha Morrell | Chief Medical officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 16,620 | 16,620 | - | - | Stock Option (Right to Buy) | |
| Rebecca Kuhn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 16,620 | 16,620 | - | - | Stock Option (Right to Buy) | |
| Rebecca Kuhn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 8,310 | 11,536 | - | 0 | Common Stock | |
| Irina Ridley | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 5,770 | 8,122 | - | 0 | Common Stock | |
| Irina Ridley | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 11,540 | 11,540 | - | - | Stock Option (Right to Buy) | |
| Frank M. Fischer | Director | 26 Apr 2021 | 21,486 | 0 | - | - | Series A Preferred Stock | ||
| Frank M. Fischer | Director | 26 Apr 2021 | 472,366 | 565,657 | - | 0 | Common Stock | ||
| Frank M. Fischer | Director | 26 Apr 2021 | 450,880 | 0 | - | - | Series B Preferred Stock | ||
| Joseph A. Lacob | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2021 | 334,027 | 351,920 | - | 0 | Common Stock | |
| Joseph A. Lacob | Director | 26 Apr 2021 | 8,594 | 0 | - | - | Series A Preferred Stock | ||
| Joseph A. Lacob | Director | 26 Apr 2021 | 17,189 | 0 | - | - | Series A Preferred Stock | ||
| Joseph A. Lacob | Director | 26 Apr 2021 | 205,497 | 0 | - | - | Series B Preferred Stock | ||
| Joseph A. Lacob | Director | 26 Apr 2021 | 102,747 | 0 | - | - | Series B; Preferred Stock | ||
| Greg S. Garfield | Director | 26 Apr 2021 | 859 | 0 | - | - | Series A Preferred Stock | ||
| Greg S. Garfield | Director | 26 Apr 2021 | 5,271,902 | 0 | - | - | Series B Preferred Stock | ||
| Greg S. Garfield | Director | 26 Apr 2021 | 323,591 | 0 | - | - | Series A Preferred Stock | ||
| Greg S. Garfield | Director | 26 Apr 2021 | 18,032 | 0 | - | - | Series B Preferred Stock | ||
| Greg S. Garfield | Director | 26 Apr 2021 | 5,595,493 | 5,614,384 | - | 0 | Common Stock | ||
| Greg S. Garfield | Director | 26 Apr 2021 | 18,891 | 18,891 | - | 0 | Common Stock | ||
| Michael Favet | Director, Chief Executive Officer | 26 Apr 2021 | 343 | 0 | - | - | Series A Preferred Stock | ||
| Michael Favet | Director, Chief Executive Officer | 26 Apr 2021 | 7,562 | 7,562 | - | 0 | Common Stock | ||
| Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.03 per share. | 26 Apr 2021 | 15,385 | 22,947 | - | 0.0 | 462 | Common Stock |
| Michael Favet | Director, Chief Executive Officer | 26 Apr 2021 | 7,219 | 0 | - | - | Series B Preferred Stock | ||
| Evan Norton | Director | 26 Apr 2021 | 3,454,422 | 0 | - | - | Series B Preferred Stock | ||
| Evan Norton | Director | 26 Apr 2021 | 3,454,422 | 4,042,657 | - | 0 | Common Stock | ||
| Joseph A. Lacob | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 21,698 | 21,698 | - | - | Stock Option (Right to Buy) | |
| Rakhi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 21,698 | 21,698 | - | - | Stock Option (Right to Buy) | |
| Evan Norton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 21,698 | 21,698 | - | - | Stock Option (Right to Buy) | |
| Renee Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 21,698 | 21,698 | - | - | Stock Option (Right to Buy) |